Transgene

Transgene Financing Cash Flow

The Net Financing Cash Flow of Transgene (TNG.PA) as of Nov 18, 2026 is 26.96 M EUR. In the previous year, Net Financing Cash Flow was 11.37 M EUR — a change of 137.13% (higher).

Financing Cash Flow

26.96 MEUR

YoY

137.13%

Last updated:

Net Financing Cash Flow of Transgene is 2024 26.96 M EUR. Net Financing Cash Flow of Transgene was 2023 11.37 M EUR. It decreases by 137.13% higher compared to the previous year.

The Transgene Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
32.52 M EUR
Jan 1, 2018
30.02 M EUR
Jan 1, 2019
22.40 M EUR
Jan 1, 2020
14.94 M EUR
Jan 1, 2021
32.32 M EUR
Jan 1, 2022
-1.48 M EUR
Jan 1, 2023
11.37 M EUR
Jan 1, 2024
26.96 M EUR
The Transgene Financing Cash Flow history
YEARFinancing Cash FlowYoY
26.96 MEUR+137.13%
11.37 MEUR-869.74%
-1.48 MEUR-104.57%
32.32 MEUR+116.32%
14.94 MEUR-33.30%
22.40 MEUR-25.38%
30.02 MEUR-7.70%
32.52 MEUR-12.62%
37.22 MEUR-12.58%
42.58 MEUR-18.21%
52.06 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Financing Cash Flow of Transgene is 26.96 M EUR in 2024.

Net Financing Cash Flow of Transgene changed from 11.37 M EUR to 26.96 M EUR, representing a 137.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Transgene since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene